Cell Responses to IFN-gamma
This study has been terminated.
(Unable to isolate sufficient cells from the skin biopsy to perform study experiments.)
Information provided by (Responsible Party):
First received: March 10, 2011
Last updated: March 4, 2013
Last verified: March 2013
IFN-gamma is a central player in the development of psoriasis lesions, which can be involved a variety of cellular processes in the skin. Dendritic cells are important cells in driving inflammation in psoriasis through the induction of T cells that produce IL-17 in psoriasis. Injecting IFN-g into the skin can increase the numbers of T cells and also inflammatory DCs that produce cytokines involved in IL-17 production. Thus, the investigators hypothesize that the dendritic cells present in the skin after IFN-g injection polarize IL-17-producing T cells.
||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
||Cellular Responses To Intradermal-Gamma (IFN-gamma) in Normal and Psoriatic Patients
Primary Outcome Measures:
Secondary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||May 2011 (Final data collection date for primary outcome measure)
- All subjects will receive one intradermal injections of 0.25ml of IFN-g (Actimmune TM 100 micrograms/0.5ml), in normal appearing skin of both normal volunteers and psoriasis patients.
- Blood will be taken at baseline and day 1. A skin biopsy (6mm punch) will be taken at the injection site 24 hours later.
- Patients will return at one to two weeks for suture removal.
- Clinical assessments done at every visit.
- Patients will also be evaluated at each visit for any adverse events.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Signed informed consent
- Normal volunteers with no evidence of skin disease OR diagnosis of plaque type psoriasis for at least 6 months
- 18 years of age or greater
- For women of childbearing potential or in men whose partners may become pregnant, willingness to use an acceptable method of contraception to prevent pregnancy for the duration of the study. Acceptable methods of contraception include use of a condom; abstinence; use by sexual partner of oral implantable or injectable contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap; or a sterile sexual partner
- Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis
- Clinically significant psoriasis flare during screening or on the first treatment day
- Hypersensitivity to IFN-g or E. coli derivatives
- Pre-existing, uncontrolled myelosuppression, cardiac disease, seizure disorders, compromised central nervous system function or multiple sclerosis
- History of malignancy, clinically significant renal insufficiency, poorly controlled medical conditions that would increase the risks
- Presence of malignancy within the past 5 years, including lymphoproliferative disorders. Subjects with a history of fully resolved basal cell or squamous cell skin cancer may be enrolled.
- Pregnancy or lactation. As the risk of IFN-g in pregnancy is unknown, pregnant women will be excluded from the study.
- Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to study drug
Please refer to this study by its ClinicalTrials.gov identifier: NCT01317017
|New York, New York, United States, 10065 |
||Michelle Lowes, MD
||The Rockefeller University
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 10, 2011
||March 4, 2013
||United States: Institutional Review Board
Keywords provided by Rockefeller University:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 06, 2014
Skin Diseases, Papulosquamous